Lymphokine-activated killer (LAK) cell anti-HIV-1 adcc reactivity: A potential strategy for reduction of virus-infected cellular reservoirs

Douglas S. Tyler; S. David Stanley; John A. Bartlett; Dani P. Bolognesi; Kent J. Weinhold

doi:10.1006/jsre.1998.5415

Lymphokine-activated killer (LAK) cell anti-HIV-1 adcc reactivity: A potential strategy for reduction of virus-infected cellular reservoirs

Douglas S. Tyler, S. David Stanley, John A. Bartlett, Dani P. Bolognesi, Kent J. Weinhold

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Lymphocytes from HIV-1-seropositive and -seronegative individuals were examined to determine whether HIV-1 infection interfered with the ability to generate a lymphokine-activated killer (LAK) cell response. Following a 3- day ex vivo incubation in the presence of 1000 U/ml of recombinant interleukin-2, lymphocytes from seropositive individuals exhibited a LAK cell response which was equivalent to or greater than that of seronegative controls as measured against Daudi cell targets. LAK cells from seropositive and seronegative donors showed no specific cytolytic activity against gp120- coated or HIV-1-infected targets. However, in the presence of patient sera, significant levels of virus-specific LAK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) were observed. The level of this specific LAK cell-mediated ADCC was greater than that mediated under similar conditions by freshly isolated peripheral blood mononuclear cells. The greatest improvement in ADCC over baseline activity was seen with lymphocytes from AIDS patients after the 3-day ex vivo activation, suggesting that this patient population might benefit the most from adaptive LAK cell therapy.

Original language	English (US)
Pages (from-to)	115-120
Number of pages	6
Journal	Journal of Surgical Research
Volume	79
Issue number	2
DOIs	https://doi.org/10.1006/jsre.1998.5415
State	Published - Oct 1998
Externally published	Yes

Keywords

ADCC
Interleukin-2
LAK cells
NK/K cells

ASJC Scopus subject areas

Surgery

Access to Document

10.1006/jsre.1998.5415

Cite this

@article{d3d3cc99206041f5bf5723a9921e3293,

title = "Lymphokine-activated killer (LAK) cell anti-HIV-1 adcc reactivity: A potential strategy for reduction of virus-infected cellular reservoirs",

abstract = "Lymphocytes from HIV-1-seropositive and -seronegative individuals were examined to determine whether HIV-1 infection interfered with the ability to generate a lymphokine-activated killer (LAK) cell response. Following a 3- day ex vivo incubation in the presence of 1000 U/ml of recombinant interleukin-2, lymphocytes from seropositive individuals exhibited a LAK cell response which was equivalent to or greater than that of seronegative controls as measured against Daudi cell targets. LAK cells from seropositive and seronegative donors showed no specific cytolytic activity against gp120- coated or HIV-1-infected targets. However, in the presence of patient sera, significant levels of virus-specific LAK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) were observed. The level of this specific LAK cell-mediated ADCC was greater than that mediated under similar conditions by freshly isolated peripheral blood mononuclear cells. The greatest improvement in ADCC over baseline activity was seen with lymphocytes from AIDS patients after the 3-day ex vivo activation, suggesting that this patient population might benefit the most from adaptive LAK cell therapy.",

keywords = "ADCC, Interleukin-2, LAK cells, NK/K cells",

author = "Tyler, {Douglas S.} and Stanley, {S. David} and Bartlett, {John A.} and Bolognesi, {Dani P.} and Weinhold, {Kent J.}",

note = "Funding Information: 1This work is supported by NIH Grants RO1-AI29852 and P3O-AI28662. 2Douglas S. Tyler is the recipient of an American College of Surgeons Faculty Fellowship Award.",

year = "1998",

month = oct,

doi = "10.1006/jsre.1998.5415",

language = "English (US)",

volume = "79",

pages = "115--120",

journal = "Journal of Surgical Research",

issn = "0022-4804",

publisher = "Academic Press Inc.",

number = "2",

}

TY - JOUR

T1 - Lymphokine-activated killer (LAK) cell anti-HIV-1 adcc reactivity

T2 - A potential strategy for reduction of virus-infected cellular reservoirs

AU - Tyler, Douglas S.

AU - Stanley, S. David

AU - Bartlett, John A.

AU - Bolognesi, Dani P.

AU - Weinhold, Kent J.

N1 - Funding Information: 1This work is supported by NIH Grants RO1-AI29852 and P3O-AI28662. 2Douglas S. Tyler is the recipient of an American College of Surgeons Faculty Fellowship Award.

PY - 1998/10

Y1 - 1998/10

N2 - Lymphocytes from HIV-1-seropositive and -seronegative individuals were examined to determine whether HIV-1 infection interfered with the ability to generate a lymphokine-activated killer (LAK) cell response. Following a 3- day ex vivo incubation in the presence of 1000 U/ml of recombinant interleukin-2, lymphocytes from seropositive individuals exhibited a LAK cell response which was equivalent to or greater than that of seronegative controls as measured against Daudi cell targets. LAK cells from seropositive and seronegative donors showed no specific cytolytic activity against gp120- coated or HIV-1-infected targets. However, in the presence of patient sera, significant levels of virus-specific LAK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) were observed. The level of this specific LAK cell-mediated ADCC was greater than that mediated under similar conditions by freshly isolated peripheral blood mononuclear cells. The greatest improvement in ADCC over baseline activity was seen with lymphocytes from AIDS patients after the 3-day ex vivo activation, suggesting that this patient population might benefit the most from adaptive LAK cell therapy.

AB - Lymphocytes from HIV-1-seropositive and -seronegative individuals were examined to determine whether HIV-1 infection interfered with the ability to generate a lymphokine-activated killer (LAK) cell response. Following a 3- day ex vivo incubation in the presence of 1000 U/ml of recombinant interleukin-2, lymphocytes from seropositive individuals exhibited a LAK cell response which was equivalent to or greater than that of seronegative controls as measured against Daudi cell targets. LAK cells from seropositive and seronegative donors showed no specific cytolytic activity against gp120- coated or HIV-1-infected targets. However, in the presence of patient sera, significant levels of virus-specific LAK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) were observed. The level of this specific LAK cell-mediated ADCC was greater than that mediated under similar conditions by freshly isolated peripheral blood mononuclear cells. The greatest improvement in ADCC over baseline activity was seen with lymphocytes from AIDS patients after the 3-day ex vivo activation, suggesting that this patient population might benefit the most from adaptive LAK cell therapy.

KW - ADCC

KW - Interleukin-2

KW - LAK cells

KW - NK/K cells

UR - http://www.scopus.com/inward/record.url?scp=0032189347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032189347&partnerID=8YFLogxK

U2 - 10.1006/jsre.1998.5415

DO - 10.1006/jsre.1998.5415

M3 - Article

C2 - 9758725

AN - SCOPUS:0032189347

SN - 0022-4804

VL - 79

SP - 115

EP - 120

JO - Journal of Surgical Research

JF - Journal of Surgical Research

IS - 2

ER -

Lymphokine-activated killer (LAK) cell anti-HIV-1 adcc reactivity: A potential strategy for reduction of virus-infected cellular reservoirs

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this